Prilenia

CompanyIsrael

Prilenia develops one asset, in phase 3 (pridopidine in amyotrophic lateral sclerosis). Mostly small molecule acting on SIGMAR1; based in Israel.

1
Asset
Furthest stage: Phase 3; 2
Trials: 0
Signals

Pipeline

1

pridopidine
Selective sigma-1 receptor agonist promoting neuroprotective pathways.
Phase 3, Small molecule, SIGMAR1, amyotrophic lateral sclerosis, Huntington's disease

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms1
Trials2
Signals6
Similar companies6